220 related articles for article (PubMed ID: 21443470)
21. Coumarins scaffolds as COX inhibitors.
Revankar HM; Bukhari SN; Kumar GB; Qin HL
Bioorg Chem; 2017 Apr; 71():146-159. PubMed ID: 28222891
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer.
Clària J; Romano M
Curr Pharm Des; 2005; 11(26):3431-47. PubMed ID: 16250846
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Saito T; Tamura D; Asano R
Oncol Rep; 2014 Apr; 31(4):1637-44. PubMed ID: 24503782
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.
Ko SH; Choi GJ; Lee JH; Han YA; Lim SJ; Kim SH
Oncol Rep; 2008 Feb; 19(2):425-33. PubMed ID: 18202791
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Grösch S; Maier TJ; Schiffmann S; Geisslinger G
J Natl Cancer Inst; 2006 Jun; 98(11):736-47. PubMed ID: 16757698
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
Attiga FA; Fernandez PM; Weeraratna AT; Manyak MJ; Patierno SR
Cancer Res; 2000 Aug; 60(16):4629-37. PubMed ID: 10969817
[TBL] [Abstract][Full Text] [Related]
27. Cancer and cyclooxygenase-2 (COX-2) inhibition.
Evans JF; Kargman SL
Curr Pharm Des; 2004; 10(6):627-34. PubMed ID: 14965325
[TBL] [Abstract][Full Text] [Related]
28. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS
J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 as a target for anticancer drug development.
Méric JB; Rottey S; Olaussen K; Soria JC; Khayat D; Rixe O; Spano JP
Crit Rev Oncol Hematol; 2006 Jul; 59(1):51-64. PubMed ID: 16531064
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
Deasy BM; O'Sullivan-Coyne G; O'Donovan TR; McKenna SL; O'Sullivan GC
Cancer Lett; 2007 Oct; 256(2):246-58. PubMed ID: 17707579
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2 and prostate carcinogenesis.
Hussain T; Gupta S; Mukhtar H
Cancer Lett; 2003 Mar; 191(2):125-35. PubMed ID: 12618325
[TBL] [Abstract][Full Text] [Related]
32. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
33. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
Shureiqi I; Chen D; Lotan R; Yang P; Newman RA; Fischer SM; Lippman SM
Cancer Res; 2000 Dec; 60(24):6846-50. PubMed ID: 11156377
[TBL] [Abstract][Full Text] [Related]
34. Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade.
Sala A; Proschak E; Steinhilber D; Rovati GE
Biochem Pharmacol; 2018 Dec; 158():161-173. PubMed ID: 30315753
[TBL] [Abstract][Full Text] [Related]
35. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
[TBL] [Abstract][Full Text] [Related]
36. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
[TBL] [Abstract][Full Text] [Related]
37. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Xu HB; Shen FM; Lv QZ
Eur J Pharmacol; 2015 Dec; 769():1-7. PubMed ID: 26407653
[TBL] [Abstract][Full Text] [Related]
38. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?
Liao Z; Mason KA; Milas L
Drugs; 2007; 67(6):821-45. PubMed ID: 17428102
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase 2: a molecular target for cancer prevention and treatment.
Subbaramaiah K; Dannenberg AJ
Trends Pharmacol Sci; 2003 Feb; 24(2):96-102. PubMed ID: 12559775
[TBL] [Abstract][Full Text] [Related]
40. COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
Voloshyna I; Kasselman LJ; Carsons SE; Littlefield MJ; Gomolin IH; De Leon J; Reiss AB
J Investig Med; 2017 Mar; 65(3):694-704. PubMed ID: 27940550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
